25 January 2021 - Theranica today announced that its Nerivio therapeutic device has received the FDA clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and old.

Theranica's FDA cleared prescribed therapeutic wearable Nerivio is worn on the upper arm for 45 minutes, and utilizes Remote Electrical Neuromodulation to activate the brain's native Conditioned Pain Modulation mechanism to treat pain and associated migraine symptoms. 

Nerivio was cited as one of TIME's best inventions of 2019.

Read Theranica press release